Compare BridgeBio Pharma Inc (BBIO) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Medtronic PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Medtronic PLC trades at $90.51 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 7.1× BridgeBio Pharma Inc's market cap, and Medtronic PLC pays a 3.18% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MDT | |
|---|---|---|
Market Cap | $16.36B | $116.07B |
Sector | Health | Health |
52-Week High | $90.17 | $105.35 |
52-Week Low | $47.29 | $73.75 |
Enterprise Value | $18.14B | $134.82B |
Dividend Yield | — | 3.18% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
